Wisconsin Assembly Bill AB717

Wisconsin 2025-2026 Regular Session

• Introduced: 12/3/25
• Refer: 12/3/25
• Report Pass: 1/22/26
• Refer: 1/22/26
• Refer: 2/13/26
• Failed: 3/23/26

Caption

Listing of carfentanil under the Uniform Controlled Substances Act and providing a penalty.

Impact

The impact of AB717 would be substantial in the realm of drug regulation and law enforcement policy in Wisconsin. The bill introduces new felony classifications based on the quantities of carfentanil involved in offenses. Specifically, possession, manufacture, or distribution of carfentanil could classify as a Class E felony for amounts of 10 grams or less, escalating to Class C felonies for greater amounts. This establishes a clearer legal framework for prosecuting offenses related to carfentanil, aligning with national trends to tighten laws against powerful synthetic opioids.

Summary

Assembly Bill 717 (AB717) proposes a significant modification to the classification of carfentanil under the Uniform Controlled Substances Act by reclassifying it from a synthetic opiate listed under Schedule II to a fentanyl analog categorized under Schedule I. This change reflects growing concerns over the dangers posed by carfentanil, a potent synthetic opioid often associated with illicit drug trafficking and fatal overdoses. By elevating its scheduling, AB717 aims to impose stricter regulations and enhance law enforcement's ability to combat the misuse of this substance.

Contention

Discussion surrounding AB717 may invoke contention particularly regarding its implications for sentencing and the broader approach to drug-related offenses. Proponents are likely to argue that the bill is a crucial step toward fighting the opioid epidemic and addressing public safety concerns. Conversely, critics may argue that increasing penalties may not effectively deter drug-related crimes and could contribute to overcrowding in jails without addressing the root causes of addiction or providing avenues for treatment.